Sanofi-aventis announces NEJM published positive BSI-201 phase II results for breast

[News]

Sanofi-aventis and its wholly-owned subsidiary, BiPar Sciences, today announced that The New England Journal of Medicine published the final phase II data for the investigational drug iniparib demonstrating significant clinical benefit in women with metastatic triple negative breast cancer when iniparib was administered in combination with chemotherapy agents gemcitabine/carboplatin.

More... (http://www.news-medical.net/news/20110106/Sanofi-aventis-announces-NEJM-published-positive-BSI-201-phase-II-results-for-breast-cancer.aspx)